Latest Lead News

Cuscal Limited has received final regulatory approval from APRA for its full acquisition of Indue Limited, setting the stage for completion by early December.

Saferoads Holdings has divested its Road Safety Rentals business for $10.8 million, repaid debt, and is now focusing on rebuilding its core product sales with new hires and product innovation.

Buru Energy has issued 52.5 million attaching options to shareholders involved in its recent placement, following shareholder approval at the November 18 General Meeting.

Charter Hall Group reported solid FY25 financial results with significant earnings growth and sustainability milestones, while guiding higher earnings and distributions for FY26.

Charter Hall Group has raised its FY26 operating earnings per security guidance by 5.5%, reflecting robust momentum in property investments and funds management. The upgrade signals growing investor confidence and increased transaction volumes across its platforms.

HomeCo Daily Needs REIT has announced a quarterly cash distribution of 2.15 cents per unit for Q3 2025, including a fund payment component under Australian tax law. The REIT confirms its tax structure intentions for the 2026 financial year.

Renegade Exploration has identified the Myschka prospect in Canada’s Yukon as a promising Reduced Intrusion-Related Gold System, with plans underway for maiden drilling in 2026. High-grade silver, gold, and antimony samples reinforce its potential within the prolific Tombstone Gold Belt.

Cyprium Metals has secured board approval to restart copper cathode production at its Nifty Copper Complex, targeting first output by mid-2026. The plan leverages existing heap leach resources and refurbishes key processing infrastructure to generate near-term cash flow.

ReadCloud Limited reported a 5% revenue increase to $12.9 million for FY25, alongside a 109% surge in underlying EBITDA to $0.76 million, narrowing its statutory loss by 59%. Strong growth in its VET-in-Schools segment and domestic eBooks sales underpinned this improved financial performance.

Amplia Therapeutics has secured positive feedback from the US FDA on its Phase 2b/3 trial design for narmafotinib in pancreatic cancer, paving the way for a late 2026 trial start.

IPH Limited reported solid FY25 profit growth driven by Canadian acquisitions and a promising FY26 start despite challenges in Australia and New Zealand. CEO Andrew Blattman announced his retirement for late 2026, marking a pivotal leadership transition.

Aspermont Limited has appointed John Stark and David Straface as interim directors, reinforcing its board with seasoned insiders during a pivotal growth phase focused on data and intelligence services for global resource sectors.